Recent uptake of COVID-19 vaccine booster doses in the European Union has been “rather disappointing,” an official said on Thursday, amid concerns that protection against severe cases of the disease could weaken during the winter.
Sanofi said on Thursday it won European Union approval for its COVID-19 vaccine booster, jointly made with British partner GSK, after a drawn-out development effort that saw the pair fall behind now-dominant vaccine suppliers.
An official at the European Union’s drugs regulator said on Tuesday the COVID-19 pandemic was not over, contradicting U.S. President Joe Biden, and that a planned vaccination campaign in the region during the cold season was key to fighting it.
France’s national health body warned on Friday of a resurgence of COVID-19 cases in the country, and urged people to continue to get vaccinated to protect themselves against the virus.
AstraZeneca said on Friday its drug for preventing infant RSV, Beyfortus (nirsevimab), was recommended for approval in the European Union by a European Medicines Agency committee.
Demand for booster vaccinations against COVID-19 is low in Germany, the association of general practitioners said on Thursday, with some patients waiting for a booster designed to combat the currently circulating Omicron BA.4/5 subvariants.
People in Europe should take whatever COVID-19 booster is available to them in the coming months, Emer Cooke, Executive Director of the European Medicines Agency (EMA), said in a Reuters Next Newsmaker interview, ahead of an expected autumn rise in infections.
The European Medicines Agency (EMA) on Monday recommended a COVID-19 booster designed to combat Omicron offshoots BA.4/5, days after endorsing a pair of boosters tailored to target the older BA.1 variant.
The European Union’s drugs regulator may be a few weeks from deciding whether to approve the experimental COVID-19 vaccine developed by French drugmaker Sanofi and its British partner GSK, a Sanofi executive said on Monday.
The European Union’s drug regulator on Thursday backed two separate COVID-19 vaccine boosters updated to target the Omicron variant, ahead of an anticipated rise in infections this winter.